J Ethnopharmacol: 合肥研究院在灵芝抗癌药理研究方面取得进展

2020-08-20 合肥研究院 中国生物技术网

近期,中国科学院合肥物质科学研究院智能机械研究所离子束生物工程与绿色农业研究中心研究员黄青课题组在灵芝抗癌药理研究方面取得新进展,发现灵芝酸D可以同时诱导食管鳞癌细胞凋亡和自噬性细胞死亡。

近期,中国科学院合肥物质科学研究院智能机械研究所离子束生物工程与绿色农业研究中心研究员黄青课题组在灵芝抗癌药理研究方面取得新进展,发现灵芝酸D可以同时诱导食管鳞癌细胞凋亡和自噬性细胞死亡。相关研究结果发表在药理研究期刊Journal of Ethnopharmacology上。   

灵芝作为一种传统的中药已有两千多年的药用历史,并具有多种药用价值。其中,灵芝酸是灵芝中具有抗肿瘤、抑制细胞增殖等作用的重要药理成分,但是其具体作用机制还有许多问题有待研究阐明。   

近年来,黄青课题组一直开展灵芝育种及功能开发研究。该研究主要围绕灵芝酸对癌细胞的作用机制进行,结果表明,灵芝酸在不同的作用时间和不同剂量上都会显著降低食管鳞癌细胞的细胞活力,并且随着剂量的增加显著阻断细胞周期在G2/M期。灵芝酸不仅可以诱导凋亡,同时还可以诱导细胞自噬的发生。通过检测自噬的标志蛋白(LC3、P62、Beclin-1),显示灵芝酸可以增加自噬小体的表达。通过自噬双荧光标记(GFP-RFP-LC3)方法进一步检测自噬流时,发现灵芝酸可以阻断自噬流,通过阻断自噬小体和溶酶体的融合,造成自噬性细胞死亡。   

进一步分析发现,灵芝酸降低了溶酶体膜蛋白(LAMP-2)的表达,使用Mito-tracker荧光探针标记溶酶体发现灵芝酸中和溶酶体酸性,结果导致溶酶体无法与自噬小体融合,造成自噬流的阻断导致细胞死亡。同时也发现灵芝酸与氯喹的联合使用,能较显著增加细胞凋亡比例。通过加入caspase蛋白的抑制剂(Z-VAD-FMK)后分析细胞活力、caspase、LC3等表达变化,进一步验证了灵芝酸可以诱导自噬性细胞死亡的发生。在分子水平上,灵芝酸通过介导PI3K/AKT/mTOR通路,降低AKT蛋白磷酸化水平引发caspase通路的细胞凋亡,同时降低mTOR蛋白磷酸化水平诱导自噬发生,造成自噬流阻断,产生自噬性细胞死亡。该项研究为灵芝酸作为抗肿瘤佐剂应用于食管鳞癌的治疗提供了理论依据和支持。   

该研究工作得到国家自然科学基金以及横向课题等的支持。

 

a:灵芝酸诱导食管鳞癌细胞凋亡和自噬性细胞死亡的总示意图 b:灵芝酸阻断自噬流造成自噬性细胞死亡的示意图

原始出处:Chang-ShengShao, Xiu-HongZhou, Xin-XinZheng, et al. Ganoderic acid D induces synergistic autophagic cell death except for apoptosis in ESCC cells. J Ethnopharmacol. 15 November 2020

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1788402, encodeId=c7b91e884026a, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Jun 14 15:29:18 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908603, encodeId=049c19086033e, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Mar 18 04:29:18 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787682, encodeId=45541e876826f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Apr 22 10:29:18 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811389, encodeId=a89418113898c, content=<a href='/topic/show?id=55658e92400' target=_blank style='color:#2F92EE;'>#药理研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87924, encryptionId=55658e92400, topicName=药理研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Jan 08 10:29:18 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996369, encodeId=6d411996369b9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Aug 31 06:29:18 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314885, encodeId=64201314885a0, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Aug 22 02:29:18 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811466, encodeId=da04811466af, content=为中华灵芝宝打call, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5925394177, createdName=萧山yd, createdTime=Thu Aug 20 17:52:10 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811392, encodeId=918381139270, content=<a href='/topic/show?id=9df266946f9' target=_blank style='color:#2F92EE;'>#灵芝#</a>抗癌,<a href='/topic/show?id=ccf410109188' target=_blank style='color:#2F92EE;'>#食管癌#</a>,但是靠谱性令人怀疑。毕竟还是基础研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66946, encryptionId=9df266946f9, topicName=灵芝), TopicDto(id=101091, encryptionId=ccf410109188, topicName=食管癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Aug 20 12:30:14 CST 2020, time=2020-08-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1788402, encodeId=c7b91e884026a, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Jun 14 15:29:18 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908603, encodeId=049c19086033e, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Mar 18 04:29:18 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787682, encodeId=45541e876826f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Apr 22 10:29:18 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811389, encodeId=a89418113898c, content=<a href='/topic/show?id=55658e92400' target=_blank style='color:#2F92EE;'>#药理研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87924, encryptionId=55658e92400, topicName=药理研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Jan 08 10:29:18 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996369, encodeId=6d411996369b9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Aug 31 06:29:18 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314885, encodeId=64201314885a0, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Aug 22 02:29:18 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811466, encodeId=da04811466af, content=为中华灵芝宝打call, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5925394177, createdName=萧山yd, createdTime=Thu Aug 20 17:52:10 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811392, encodeId=918381139270, content=<a href='/topic/show?id=9df266946f9' target=_blank style='color:#2F92EE;'>#灵芝#</a>抗癌,<a href='/topic/show?id=ccf410109188' target=_blank style='color:#2F92EE;'>#食管癌#</a>,但是靠谱性令人怀疑。毕竟还是基础研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66946, encryptionId=9df266946f9, topicName=灵芝), TopicDto(id=101091, encryptionId=ccf410109188, topicName=食管癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Aug 20 12:30:14 CST 2020, time=2020-08-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1788402, encodeId=c7b91e884026a, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Jun 14 15:29:18 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908603, encodeId=049c19086033e, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Mar 18 04:29:18 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787682, encodeId=45541e876826f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Apr 22 10:29:18 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811389, encodeId=a89418113898c, content=<a href='/topic/show?id=55658e92400' target=_blank style='color:#2F92EE;'>#药理研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87924, encryptionId=55658e92400, topicName=药理研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Jan 08 10:29:18 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996369, encodeId=6d411996369b9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Aug 31 06:29:18 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314885, encodeId=64201314885a0, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Aug 22 02:29:18 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811466, encodeId=da04811466af, content=为中华灵芝宝打call, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5925394177, createdName=萧山yd, createdTime=Thu Aug 20 17:52:10 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811392, encodeId=918381139270, content=<a href='/topic/show?id=9df266946f9' target=_blank style='color:#2F92EE;'>#灵芝#</a>抗癌,<a href='/topic/show?id=ccf410109188' target=_blank style='color:#2F92EE;'>#食管癌#</a>,但是靠谱性令人怀疑。毕竟还是基础研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66946, encryptionId=9df266946f9, topicName=灵芝), TopicDto(id=101091, encryptionId=ccf410109188, topicName=食管癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Aug 20 12:30:14 CST 2020, time=2020-08-20, status=1, ipAttribution=)]
    2021-04-22 jj000001
  4. [GetPortalCommentsPageByObjectIdResponse(id=1788402, encodeId=c7b91e884026a, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Jun 14 15:29:18 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908603, encodeId=049c19086033e, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Mar 18 04:29:18 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787682, encodeId=45541e876826f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Apr 22 10:29:18 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811389, encodeId=a89418113898c, content=<a href='/topic/show?id=55658e92400' target=_blank style='color:#2F92EE;'>#药理研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87924, encryptionId=55658e92400, topicName=药理研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Jan 08 10:29:18 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996369, encodeId=6d411996369b9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Aug 31 06:29:18 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314885, encodeId=64201314885a0, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Aug 22 02:29:18 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811466, encodeId=da04811466af, content=为中华灵芝宝打call, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5925394177, createdName=萧山yd, createdTime=Thu Aug 20 17:52:10 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811392, encodeId=918381139270, content=<a href='/topic/show?id=9df266946f9' target=_blank style='color:#2F92EE;'>#灵芝#</a>抗癌,<a href='/topic/show?id=ccf410109188' target=_blank style='color:#2F92EE;'>#食管癌#</a>,但是靠谱性令人怀疑。毕竟还是基础研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66946, encryptionId=9df266946f9, topicName=灵芝), TopicDto(id=101091, encryptionId=ccf410109188, topicName=食管癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Aug 20 12:30:14 CST 2020, time=2020-08-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1788402, encodeId=c7b91e884026a, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Jun 14 15:29:18 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908603, encodeId=049c19086033e, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Mar 18 04:29:18 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787682, encodeId=45541e876826f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Apr 22 10:29:18 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811389, encodeId=a89418113898c, content=<a href='/topic/show?id=55658e92400' target=_blank style='color:#2F92EE;'>#药理研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87924, encryptionId=55658e92400, topicName=药理研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Jan 08 10:29:18 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996369, encodeId=6d411996369b9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Aug 31 06:29:18 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314885, encodeId=64201314885a0, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Aug 22 02:29:18 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811466, encodeId=da04811466af, content=为中华灵芝宝打call, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5925394177, createdName=萧山yd, createdTime=Thu Aug 20 17:52:10 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811392, encodeId=918381139270, content=<a href='/topic/show?id=9df266946f9' target=_blank style='color:#2F92EE;'>#灵芝#</a>抗癌,<a href='/topic/show?id=ccf410109188' target=_blank style='color:#2F92EE;'>#食管癌#</a>,但是靠谱性令人怀疑。毕竟还是基础研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66946, encryptionId=9df266946f9, topicName=灵芝), TopicDto(id=101091, encryptionId=ccf410109188, topicName=食管癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Aug 20 12:30:14 CST 2020, time=2020-08-20, status=1, ipAttribution=)]
    2020-08-31 yb6560
  6. [GetPortalCommentsPageByObjectIdResponse(id=1788402, encodeId=c7b91e884026a, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Jun 14 15:29:18 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908603, encodeId=049c19086033e, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Mar 18 04:29:18 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787682, encodeId=45541e876826f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Apr 22 10:29:18 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811389, encodeId=a89418113898c, content=<a href='/topic/show?id=55658e92400' target=_blank style='color:#2F92EE;'>#药理研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87924, encryptionId=55658e92400, topicName=药理研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Jan 08 10:29:18 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996369, encodeId=6d411996369b9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Aug 31 06:29:18 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314885, encodeId=64201314885a0, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Aug 22 02:29:18 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811466, encodeId=da04811466af, content=为中华灵芝宝打call, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5925394177, createdName=萧山yd, createdTime=Thu Aug 20 17:52:10 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811392, encodeId=918381139270, content=<a href='/topic/show?id=9df266946f9' target=_blank style='color:#2F92EE;'>#灵芝#</a>抗癌,<a href='/topic/show?id=ccf410109188' target=_blank style='color:#2F92EE;'>#食管癌#</a>,但是靠谱性令人怀疑。毕竟还是基础研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66946, encryptionId=9df266946f9, topicName=灵芝), TopicDto(id=101091, encryptionId=ccf410109188, topicName=食管癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Aug 20 12:30:14 CST 2020, time=2020-08-20, status=1, ipAttribution=)]
    2020-08-22 sunylz
  7. [GetPortalCommentsPageByObjectIdResponse(id=1788402, encodeId=c7b91e884026a, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Jun 14 15:29:18 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908603, encodeId=049c19086033e, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Mar 18 04:29:18 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787682, encodeId=45541e876826f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Apr 22 10:29:18 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811389, encodeId=a89418113898c, content=<a href='/topic/show?id=55658e92400' target=_blank style='color:#2F92EE;'>#药理研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87924, encryptionId=55658e92400, topicName=药理研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Jan 08 10:29:18 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996369, encodeId=6d411996369b9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Aug 31 06:29:18 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314885, encodeId=64201314885a0, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Aug 22 02:29:18 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811466, encodeId=da04811466af, content=为中华灵芝宝打call, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5925394177, createdName=萧山yd, createdTime=Thu Aug 20 17:52:10 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811392, encodeId=918381139270, content=<a href='/topic/show?id=9df266946f9' target=_blank style='color:#2F92EE;'>#灵芝#</a>抗癌,<a href='/topic/show?id=ccf410109188' target=_blank style='color:#2F92EE;'>#食管癌#</a>,但是靠谱性令人怀疑。毕竟还是基础研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66946, encryptionId=9df266946f9, topicName=灵芝), TopicDto(id=101091, encryptionId=ccf410109188, topicName=食管癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Aug 20 12:30:14 CST 2020, time=2020-08-20, status=1, ipAttribution=)]
    2020-08-20 萧山yd

    为中华灵芝宝打call

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1788402, encodeId=c7b91e884026a, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Mon Jun 14 15:29:18 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908603, encodeId=049c19086033e, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Mar 18 04:29:18 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787682, encodeId=45541e876826f, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Apr 22 10:29:18 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811389, encodeId=a89418113898c, content=<a href='/topic/show?id=55658e92400' target=_blank style='color:#2F92EE;'>#药理研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87924, encryptionId=55658e92400, topicName=药理研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri Jan 08 10:29:18 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996369, encodeId=6d411996369b9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Aug 31 06:29:18 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314885, encodeId=64201314885a0, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Aug 22 02:29:18 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811466, encodeId=da04811466af, content=为中华灵芝宝打call, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5925394177, createdName=萧山yd, createdTime=Thu Aug 20 17:52:10 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811392, encodeId=918381139270, content=<a href='/topic/show?id=9df266946f9' target=_blank style='color:#2F92EE;'>#灵芝#</a>抗癌,<a href='/topic/show?id=ccf410109188' target=_blank style='color:#2F92EE;'>#食管癌#</a>,但是靠谱性令人怀疑。毕竟还是基础研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66946, encryptionId=9df266946f9, topicName=灵芝), TopicDto(id=101091, encryptionId=ccf410109188, topicName=食管癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Aug 20 12:30:14 CST 2020, time=2020-08-20, status=1, ipAttribution=)]
    2020-08-20 lovetcm

    #灵芝#抗癌,#食管癌#,但是靠谱性令人怀疑。毕竟还是基础研究

    0

相关资讯

Science:细胞凋亡新机制增强肿瘤治疗可能性

研究人员表示,GSDMB 存在组织特异性表达,并在消化系统上皮细胞源肿瘤细胞中呈高表达,而通过 GSDMB 诱导焦亡将增强抗肿瘤免疫,成为肿瘤治疗潜在靶点。

Cell Death & Disease:膀胱癌中氧化亚铜纳米粒子能够激活活性氧诱导的细胞凋亡

顺铂化疗是晚期膀胱癌的一线治疗方法。然而,超过50%的患者不适合进行顺铂化疗,因此开发新的治疗药物非常迫切。氧化亚铜纳米粒子(CONPs)是一种新的纳米治疗药物,在许多类型的癌症治疗中均证实是有效的。

Blood:MYC驱动的淋巴瘤进展需MYC拮抗剂MNT抑制MYC诱导的细胞凋亡

中心点:MNT通过抑制MYC诱导的细胞凋亡,来辅助MYC驱动的B淋巴细胞瘤发生,该过程主要是通过抑制BIM实现的。诱导移植的Em-Myc淋巴瘤MNT丢失可延长受体的生存期,提示MNT或可成为MYC驱动肿瘤的一个新的治疗靶点。摘要:MYC过表达失调与大多数(约70%)人类肿瘤的发生和恶性进展有关。MYC促进细胞生长和增殖,但在高水平时,也促进细胞凋亡。近期,研究人员发现MYC驱动的正常和肿瘤B淋巴样

Diabetologia:Akap1缺陷通过NDUFS1介导的线粒体功能障碍和细胞凋亡加剧了小鼠糖尿病性心肌病

糖尿病心肌病的特点是氧化损伤和线粒体功能障碍增加,进而导致糖尿病患者心力衰竭的风险增加。

PLoS One:褪黑素在预防年龄相关听力损失中的作用

年龄相关的听力损失(ARHL)是听觉系统老化的结果。ARHL中细胞死亡最清楚的机制为由于活性氧种类产生的增加导致的细胞凋亡。据此,有研究人员假设由于褪黑素具有高度的抗氧化能力和在线粒体中的作用,认为能够预防或者延迟外毛细胞的功能异常(HCD)。最近,有研究人员在一个易感的小鼠C57BL/6J模型中评估了ARHL过程中,褪黑素对HCD功能异常的预防作用情况。研究人员将C57BL/6J动物分成2个组:

NATURE:凋亡细胞释放代谢物作为“再见”信号

凋亡细胞不是等待清除的惰性细胞,而是释放代谢物作为“再见”信号,积极调节组织的结果。